166 related articles for article (PubMed ID: 23135778)
1. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
Dy GK; Infante JR; Eckhardt SG; Novello S; Ma WW; Jones SF; Huff A; Wang Q; Suttle AB; Ottesen LH; Adjei AA; Burris HA
Invest New Drugs; 2013 Aug; 31(4):891-9. PubMed ID: 23135778
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Kummar S; Srivastava AK; Navas T; Cecchi F; Lee YH; Bottaro DP; Park SR; Do KT; Jeong W; Johnson BC; Voth AR; Rubinstein L; Wright JJ; Parchment RE; Doroshow JH; Chen AP
Invest New Drugs; 2021 Dec; 39(6):1577-1586. PubMed ID: 34180036
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
Inada-Inoue M; Ando Y; Kawada K; Mitsuma A; Sawaki M; Yokoyama T; Sunakawa Y; Ishida H; Araki K; Yamashita K; Mizuno K; Nagashima F; Takekura A; Nagamatsu K; Sasaki Y
Cancer Chemother Pharmacol; 2014 Apr; 73(4):673-83. PubMed ID: 24464355
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
[TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Kotasek D; Tebbutt N; Desai J; Welch S; Siu LL; McCoy S; Sun YN; Johnson J; Adewoye AH; Price T
BMC Cancer; 2011 Jul; 11():313. PubMed ID: 21791058
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
de Jonge MJ; Hamberg P; Verweij J; Savage S; Suttle AB; Hodge J; Arumugham T; Pandite LN; Hurwitz HI
Invest New Drugs; 2013 Jun; 31(3):751-9. PubMed ID: 23054212
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
Spigel DR; Burris HA; Greco FA; Shih KC; Gian VG; Lipman AJ; Daniel DB; Waterhouse DM; Finney L; Heymach JV; Hainsworth JD
Cancer; 2018 Jun; 124(11):2355-2364. PubMed ID: 29645086
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Aggarwal R; Thomas S; Pawlowska N; Bartelink I; Grabowsky J; Jahan T; Cripps A; Harb A; Leng J; Reinert A; Mastroserio I; Truong TG; Ryan CJ; Munster PN
J Clin Oncol; 2017 Apr; 35(11):1231-1239. PubMed ID: 28221861
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
Négrier S; Pérol D; Bahleda R; Hollebecque A; Chatelut E; Boyle H; Cassier P; Metzger S; Blanc E; Soria JC; Escudier B
BMC Cancer; 2017 Aug; 17(1):547. PubMed ID: 28810837
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
Kendra KL; Plummer R; Salgia R; O'Brien ME; Paul EM; Suttle AB; Compton N; Xu CF; Ottesen LH; Villalona-Calero MA
Mol Cancer Ther; 2015 Feb; 14(2):461-9. PubMed ID: 25504632
[TBL] [Abstract][Full Text] [Related]
12. A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
Plummer R; Madi A; Jeffels M; Richly H; Nokay B; Rubin S; Ball HA; Weller S; Botbyl J; Gibson DM; Scheulen ME
Cancer Chemother Pharmacol; 2013 Jan; 71(1):93-101. PubMed ID: 23064954
[TBL] [Abstract][Full Text] [Related]
13. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
Henary H; George GC; Wheler J; Naing A; Piha-Paul S; Fu S; Mistry R; Zinner R; Kurzrock R; Hong DS
Cancer Chemother Pharmacol; 2015 Sep; 76(3):597-603. PubMed ID: 26210681
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.
Sridhar SS; Joshua AM; Gregg R; Booth CM; Murray N; Golubovic J; Wang L; Harris P; Chi KN
Clin Genitourin Cancer; 2015 Apr; 13(2):124-9. PubMed ID: 24993934
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
Soria JC; LoRusso P; Bahleda R; Lager J; Liu L; Jiang J; Martini JF; Macé S; Burris H
Oncologist; 2015 Mar; 20(3):245-6. PubMed ID: 25669662
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
Adkins D; Mehan P; Ley J; Siegel MJ; Siegel BA; Dehdashti F; Jiang X; Salama NN; Trinkaus K; Oppelt P
Lancet Oncol; 2018 Aug; 19(8):1082-1093. PubMed ID: 30001987
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
[TBL] [Abstract][Full Text] [Related]
19. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Jänne PA; Cohen RB; Laird AD; Macé S; Engelman JA; Ruiz-Soto R; Rockich K; Xu J; Shapiro GI; Martinez P; Felip E
J Thorac Oncol; 2014 Mar; 9(3):316-23. PubMed ID: 24496004
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT
Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
